Disease: nonalcoholic fatty liver disease (PMID:25623289)
Dysfunction type: NA
Description: Berberine ameliorates nonalcoholic fatty liver disease by a global modulation of hepatic mRNA and lncRNA expression profiles. MRAK052686, was found strongly correlated with the antioxidant factor Nrf2, and both genes were down-regulated by the steatotic liver. The reduced expression of MRAK052686 and Nrf2 was completely reversed by BBR treatment, suggesting a new mechanism accounting for the therapeutic effect of BBR.
Function Mechanism: NA (PMID:25623289)
Biological Process: pathogenic process
Description: therapy target